Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07100847 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Periprostatic Neurolysis in Prostate Cancer

StatusActive, Not Recruiting
PhasePhase 1
Started2025-08-15
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Aug 2026 → Jul 2027
See other at-risk trials from University of Texas Southwestern Medical Center

Amendment history

2026-09-30
critical
Primary completion pushed: 2026-08 → 2027-07
2026-07-14
notable
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v3
Trial statusRecruiting→Active, Not Recruiting
Study sitesdetails revised at 1 of 1 site
2025-09-07
minor
Study Status v2
Start dateestimated 2025-08→confirmed 2025-08-15
2025-08-24
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Study sitesdetails revised at 1 of 1 site
2025-07-27
minor
Original filing
The purpose of this research study is to assess whether inhibiting nerve activity to the prostate delays progression of disease in men with high-risk clinical features for prostate cancer. Prostate cancer has been shown to invade nerves, a mechanism that is thought to be involved in prostate cancer spread in men with high-risk cancer. When nerve activity to the prostate is blocked in mice with prostate cancer, prostate cancer growth and spread are inhibited. In a previous study we showed that doing so in humans was safe and may have anticancer therapeutic effect. In this study we will test whether one versus two injections of nerve blocking agent is more effective at reducing nerves in the prostate and whether it will slow/stop spread of prostate cancer after treatment.
Trial Details
NCT Number NCT07100847
Lead Sponsor University of Texas Southwestern Medical Center
Collaborators: Urology Care Foundation, American Urological Association
Conditions PROSTATE CANCER, NERVES, NEUROBIOLOGY OF CANCER, NEUROLYSIS
Enrollment 21 participants
Start Date 2025-08-15
Primary Completion 2027-07 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-09-29